SEC Form 4 · accession 0001144204-16-128961
INTERLEUKIN GENETICS INC · ILIU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephan Toutain
Officer — Chief Commercial Officer
Period of report
Oct 20, 2016
Accepted (ET)
Oct 21, 2016 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001037649
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $0.1754 | Oct 20, 2016 | A | 3,738,933 | A | — | Oct 20, 2026 | Common Stock | 3,738,933 | 3,738,933 | D |
Explanation of responses
- F1The exercise price of the option is the closing price of the Issuer's common stock on the OTCQB on October 20, 2016, which was the grant date of the option.
- F2The option vests as to 25% of the shares on August 15, 2017, and 1/36th of the shares on the first day of each month beginning on September 1, 2017.